ADVERTISEMENT

Novartis Cooperating With U.S. Probe Into Marketing of Entresto Heart Drug

Novartis Cooperating With U.S. Probe Into Marketing of Entresto Heart Drug

Novartis AG said it’s cooperating with a U.S. government probe of marketing practices surrounding heart drug Entresto, one of the medicines expected to drive sales growth for the Swiss pharmaceuticals giant.

The company received a Civil Investigation Demand from the Department of Justice on Sept. 22, seeking information from January 2016 to the present, a spokesman said by email on Thursday. The agency is probing marketing and pricing, including payments to health-care workers, Novartis said in a regulatory filing on Tuesday. 

There has been no determination of wrongdoing, and Novartis has a strong track record of cooperating with authorities and would expect to do so in this instance, the spokesman said. STAT reported the probe on Wednesday evening. 

Novartis raised its peak sales forecast for Entresto this week, saying annual revenue from the drug would climb to at least $5 billion. 

©2021 Bloomberg L.P.